Show simple item record

dc.contributor.authorNCD Risk Factor Collaboration
dc.date.accessioned2020-06-25T06:03:55Z
dc.date.available2020-06-25T06:03:55Z
dc.date.issued2020
dc.identifier.citationNCD Risk Factor Collaboration. (2020). Repositioning of the global epicentre of non-optimal cholesterol. <i>Nature</i>, <i>582</i>(7810), 73-77. <a href="https://doi.org/10.1038/s41586-020-2338-1" target="_blank">https://doi.org/10.1038/s41586-020-2338-1</a>
dc.identifier.otherCONVID_36038813
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/70907
dc.description.abstractHigh blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.ispartofseriesNature
dc.rightsCC BY 4.0
dc.titleRepositioning of the global epicentre of non-optimal cholesterol
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202006255097
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineLiikuntalääketiedefi
dc.contributor.oppiaineSports and Exercise Medicineen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange73-77
dc.relation.issn0028-0836
dc.relation.numberinseries7810
dc.relation.volume582
dc.type.versionpublishedVersion
dc.rights.copyright© Authors, 2020
dc.rights.accesslevelopenAccessfi
dc.subject.ysoriskitekijät
dc.subject.ysokolesteroli
dc.subject.ysoalueelliset erot
dc.subject.ysoravinto
dc.subject.ysoHDL-kolesteroli
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p13277
jyx.subject.urihttp://www.yso.fi/onto/yso/p10609
jyx.subject.urihttp://www.yso.fi/onto/yso/p7396
jyx.subject.urihttp://www.yso.fi/onto/yso/p3671
jyx.subject.urihttp://www.yso.fi/onto/yso/p16832
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1038/s41586-020-2338-1
jyx.fundinginformationThis study was funded by a Wellcome Trust (Biomedical Resource & Multi-User Equipment grant 01506/Z/13/Z) and the British Heart Foundation (Centre of Research Excellence grant RE/18/4/34215). C.T. was supported by a Wellcome Trust Research Training Fellowship (203616/Z/16/Z).
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0